

Medical Drug Recommendations by EBRx

May 2024

ASE/PSE Commission

Drug	Treating Diagnosis	EBRx	HA	Comment	Cost
Alyglo	IVIG	Exclude		Higher cost IV immune globulin, possible that SQ is more economical	\$35.76/mL
Amvuttra	Polyneuropathy of hereditary transthyretin-mediated amyloidosis	Exclude		FDA approval in June 2022 but somehow didn't make the Medical Master List. No members affected.	\$572,884 per year
Casgevy	Gene therapy for sickle cell	Exclude		Previously known as Exa-cel. Reduces incidence of severe vaso-occlusive events; long term effect unclear with risk for cancer.	\$2.2 million
Combogesic IV	IV ibuprofen/APAP	No EBRx restrictions	Covered	In patient administration under DRG	Max dose per day is \$110.40
Defencath	Prophylactic antibiotic + anticoagulant	No EBRx restrictions	Covered	Reduces risk for catheter related infection, will be wrapped into the HD payment	\$100 per mL
Eylea HD	Macular degeneration, diabetic macular edema, diabetic retinopathy	Exclude		Continue to cover Eylea, which is more cost-effective at large majority of doses. Eylea HD has limited diagnoses compared to Eylea.	Eylea = \$2,220 per 2mg/0.05mL Eylea HD = \$3,150 per 8mg/0.7mL
Ixchiq	Chikungunya vaccine	Exclude		Under review with ACIP. Virus spread via mosquitos in Asia and Africa. Travel vaccines excluded in SPD.	

Lanreotide	Tumor or acromegaly	Cover with PA on pharmacy & medical		Change allows use of copay maximizer program on pharmacy benefit and provides consistent policy across medical & pharmacy benefit	\$10,671 per SC injection
Lenmeldy	Gene therapy for Metachromatic leukodystrophy (MLD)	Exclude		MLD is typically fatal by the age of 5. If genetic tested and treated early, this can cure the patient.	\$5.1M
Lyfgenia	Gene therapy for sickle cell	Exclude		Previously known as Lovo-cel. Reduces incidence of severe vaso-occlusive events; long term effect unclear with risk for cancer.	\$3.1 million
Rivfloza	Primary hyperoxaluria (PH) type 1	Exclude		Study endpoints are surrogate markers, no evidence that it preserves kidney function	\$905,472 per year
Tezspire	Severe asthma	Exclude		Can now be self-administered. Not cost effective, alternatives available.	\$67,616 per year
Vectibix	Colorectal cancer, squamous cell carcinoma	Retire EBRx PA	Covered	None denied since 2021; EBRx criteria follows FDA approval.	\$395.50 per mL
Wainua	Polyneuropathy of hereditary transthyretin-mediated amyloidosis	Exclude		Study endpoints haven't been correlated with disease symptoms; likely not cost effective	\$598,800 per year
Zilbrysq	Generalized myasthenia gravis	Exclude		Given once daily; similar clinical effect as other options per meta-analysis; prefer lower cost options.	\$646,050 per year